Novacyt SA (NCYT)

Industry Medical Devices

Sell

37.10p

Buy

38.30p

arrow-down-0.637p (-1.68%)

Prices updated at 19 Dec 2025, 14:01 GMT

Prices minimum 15 mins delay

Prices in GBX

Novacyt SA develops and markets solutions in medical cytology. It offers portfolio of cancer and infectious disease diagnostics products and services. It has three reportable segment, Cytology, Diagnostics and Molecular Testing.

FTSE All-Share

0.42%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Medical Devices

Chairman

-

CEO

Mr. Lyn Dafydd Rees

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

234

Head office

131 Boulevard Carnot

Le Vesinet

France

78110

-

investor.relations@novacyt.co.uk

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Jean-Pierre Jacques Crinelli Non-Executive Director	-
Dr. Joanne Nicola Mason Executive Director, Chief Scientific Officer	-
Mr. Steven Michael Gibson Executive Director, Chief Financial Officer	-
Mr. Lyn Dafydd Rees Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Gestys	-
Gestys Santé Biotech	-

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.